The data de-risk ecopipam's efficacy/safety profile ahead of the FDA decision but do not change the binary regulatory outcome. Monitor the PDUFA date (not stated in release) and any AdCom announcement. Approval would be a significant catalyst for TEVA given the orphan drug pricing potential and first-in-class status.
Price Chart
Executive Summary
Teva presented new Phase 2b/3 and open-label extension data for ecopipam (D1 antagonist) in pediatric Tourette syndrome at MDS 2026, showing ~70% of patients achieved clinically meaningful tic reduction within 8 weeks and sustained mean YGTSS-TTS reduction of 45.6% at 18 months, with no new safety signals. The drug is under FDA Priority Review with a PDUFA decision pending; if approved, it would be the first novel-mechanism Tourette therapy in over 50 years. The data reinforce the approvability narrative but do not change the binary regulatory outcome — the stock catalyst remains the FDA decision.
Key Facts
- Post hoc analysis of 292 patients: 69.8% achieved ≥25% YGTSS-TTS reduction within 8 weeks of starting ecopipam.
- Interim 18-month OLE analysis (n=118, median 14.9 months exposure) showed mean YGTSS-TTS reduction of 45.6% with no new safety signals.
- Subgroup analysis (n=216) found co-occurring ADHD, OCD, anxiety, or depression did not negatively impact efficacy or safety.
- Ecopipam has FDA Priority Review and Orphan Drug designation for pediatric Tourette syndrome; NDA is under active review.
- If approved, ecopipam would be the first new Tourette therapy in >10 years and first with a novel mechanism in >50 years.
Financial Impact
Not disclosed; Teva has not provided revenue guidance for ecopipam. Tourette syndrome affects ~200,000 pediatric patients in the US; first-in-class orphan drug could generate peak sales in the hundreds of millions if approved.
Risk Factors
- FDA could issue a Complete Response Letter (CRL) on CMC or safety grounds despite positive data.
- Ecopipam is not yet approved; commercialization timeline and peak sales are uncertain.
- Teva's significant debt load (~$20B) limits financial flexibility regardless of pipeline progress.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Institutional Cluster | $41.11 | awaiting T+60 | — | $39.99 (+2.72%) |
Oct 8, 2026 17d ago | 3 | $41.10 | awaiting T+60 | — | $39.99 (−2.70%) |
Oct 2, 2026 24d ago | Press Release | $39.53 | awaiting T+60 | — | $39.99 (+1.16%) |
Oct 2, 2026 24d ago | Press Release | $39.53 | awaiting T+60 | — | $39.99 (+1.16%) |
Sep 30, 2026 25d ago | Press Release | $39.31 | awaiting T+60 | — | $39.99 (+1.73%) |
Sep 28, 2026 27d ago | Press Release | $39.81 | awaiting T+60 | — | $39.99 (+0.45%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $39.99 (−0.57%) |
Sep 23, 2026 4w ago | Press Release | $40.22 | awaiting T+60 | — | $39.99 (−0.57%) |
Sep 22, 2026 4w ago | Insider Cluster | $39.01 | awaiting T+60 | — | $39.99 (−2.51%) |
Sep 18, 2026 5w ago | Press Release | $40.05 | awaiting T+60 | — | $39.99 (−0.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers